May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

May 22, 2025

Voices on the Go: Top Podcasts for Physicians

Physicians are tuning to podcasts that combine clinical insight, career development, and storytelling.

Conexiant

May 21, 2025

Thailand Sets New Benchmark for Newborn Screening

Long-read whole genome sequencing boosts population-scale health strategy

The Pathologist

May 19, 2025

Zyrtec and Xyzal: FDA Issues Withdrawal Syndrome Warning

A new safety alert highlights the potential for severe itch following discontinuation of long-term cetirizine and levocetirizine use.

Conexiant

May 16, 2025

Delandistrogene Moxeparvovec: Efficacy Evidence Questioned

The AAN Guidelines Subcommittee review finds delandistrogene moxeparvovec for DMD failed to meet primary functional outcomes despite FDA approval.

Conexiant

May 15, 2025

FDA Approves First Oral Therapy for Pheochromocytoma and Paraganglioma

The FDA has approved a HIF-2α inhibitor for adult and pediatric patients aged 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma and paraganglioma (PPGL). 

The ASCO Post

May 14, 2025

Oral Option Now Available for PPGL

The FDA approved belzutifan as the first oral therapy for advanced pheochromocytoma and paraganglioma in patients aged 12 years and older.

Conexiant

May 05, 2025

FDA Monthly Round-up: Key April Updates

April’s FDA approvals feature first-in-class therapies, targeted biologics, expanded indications, and innovative delivery systems across allergy, endocrinology, rheumatology, oncology, infectious diseases, and more.

Conexiant

May 01, 2025

Who Is at Risk for LSCD?

Discover the vital role of limbal stem cells in maintaining ocular surface health and the challenges associated with limbal stem cell deficiency.

Contact Lens Spectrum